



# CALL FOR ROUNDTABLE DISCUSSION LEADERS

SUBMISSION DEADLINE: AUGUST 8

## DIA/FDA Oligonucleotide-Based Therapeutics Conference

OCTOBER 28-30 | WASHINGTON, DC



### CALL FOR ROUNDTABLE DISCUSSION LEADERS

SUBMISSION DEADLINE: AUGUST 8

The program committee invites you to propose and volunteer to lead a roundtable luncheon discussion at the *DIA/FDA Oligonucleotide-Based Therapeutics Conference* to be held **October 28-30 at the Capital Hilton in Washington, DC.**

Proposals must be submitted electronically. Select the following online form or copy/paste the link into your web browser:

[Online Submission Form](#)

The deadline for submission is **August 8** and selections will be sent the week of August 19. The roundtable luncheon will be held on Tuesday, October 29.

#### General guidelines for Roundtable Discussions:

- Roundtable leaders must be a registered attendee and will be responsible for all costs (e.g., registration, travel, lodging)
- Roundtable discussions are being held during a 75-minute luncheon period. The first 15-20 minutes will be allocated to attendees for gathering their lunch and finding their table assignment. The discussion period will be approximately 55-60 minutes.
- Roundtables are set up for a maximum of 6-8 participants at each table.
- Attendees will be asked to complete an online survey in advance of the conference to select a table. Those who have not selected a table in advance will be accommodated on-site on a first-come, first-served basis.
- All roundtable discussions must be noncommercial and scientific in nature and may not be used as a marketing opportunity. Any mention of drug products must be limited to generic names. Please refer to the [DIA Policy Concerning Promotion of Products and Services from the Podium at DIA-Sponsored Activities](#).

#### When submitting your proposal to lead a Roundtable, we will ask for:

1. Your name
2. Contact information
3. The roundtable discussion title (note this can be tentative)
4. A general theme/topic (examples listed below)
5. A short (2-3 sentences) description of the roundtable topic with 2-3 questions you plan to discuss
6. The submission form does not allow for edits/updates once it has been submitted. If you need to update your submission, please completely resubmit your proposal. There is a field at the end of the form to indicate that it is a resubmission.

**Submission Deadline:** August 8

**Conference Dates:** October 28-30

**Questions:** Contact Damisha White, Project Manager at [Damisha.White@DIAglobal.org](mailto:Damisha.White@DIAglobal.org)

#### Potential Roundtable topics may include (but are not limited to) the following list broad topics:

- 21st Century Cures
- PDUFA VI
- Immuno/Oncology
- Real World Evidence
- Global Regulatory Progress
- Assay Development and Optimization
- Clinical Pharmacology, including Oligonucleotides
- ADME
  - Clinical Safety
  - Formulations
- Impurities
- Manufacturing
- Nonclinical Efficacy Models
- Toxicology, including updates in Oligo-toxicology (clinical and nonclinical)
- Novel Mechanisms for Intervention
- Novel Oligonucleotide Therapeutics
- Targeting and Delivery, including Target Identification Screening
- Oligonucleotide Conjugation and Tissue Targeting
- Regulatory Affairs, including Oligonucleotide Regulatory Guidance
- Oligonucleotide Therapeutics for:
  - Rare Diseases
  - Immunoncology
  - Metabolic diseases
  - Neuromuscular Conditions
- Methods (Discovery)
- Translational Experience
- Off-target assessments
- Carcinogenicity assessment
- Interspecies scaling - w/poster
- N of 1 clinical trials

Each of these broad topics may have subtopics that you wish to expand upon in your luncheon dialogue-*feel free to be creative.*

Learn more about the Forum, visit [www.DIAglobal.org](http://www.DIAglobal.org)